|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences,_Inc.
gptkb:Gilead_Sciences
gptkb:Imbruvica
|
|
gptkbp:acquired
|
gptkb:Abb_Vie
acquired by Abb Vie
|
|
gptkbp:acquisition
|
gptkb:2015
|
|
gptkbp:approves
|
FDA approved Imbruvica in 2013
|
|
gptkbp:business_model
|
biotech
|
|
gptkbp:ceo
|
gptkb:Robert_Duggan
|
|
gptkbp:class
|
kinase inhibitors
|
|
gptkbp:clinical_trial
|
gptkb:Waldenström's_macroglobulinemia
gptkb:Chronic_lymphocytic_leukemia
gptkb:Mantle_cell_lymphoma
Phase 1
clinical trials
patient recruitment
Phase 2
Phase 3
Phase 3 trials
positive outcomes
randomized trials
Imbruvica studies
|
|
gptkbp:collaborations
|
academic institutions
research institutions
|
|
gptkbp:employees
|
approximately 500
|
|
gptkbp:focus_area
|
oncology
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Robert_Duggan
|
|
gptkbp:headquarters
|
gptkb:Silicon_Valley
gptkb:Sunnyvale,_California
|
|
gptkbp:healthcare
|
FDA approved Imbruvica
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pharmacyclics
|
|
gptkbp:indication
|
CLL and MCL
|
|
gptkbp:investment
|
gptkb:Company
Venture capital
oncology market
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
gptkb:2013
oncology drugs
|
|
gptkbp:market_cap
|
$21 billion (2020)
|
|
gptkbp:marketing_strategy
|
innovation in drug development
expansion in oncology
|
|
gptkbp:part_of
|
gptkb:Abb_Vie_Inc.
|
|
gptkbp:partnership
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:partnerships
|
biopharma companies
|
|
gptkbp:pharmacokinetics
|
high efficacy in trials
pipeline of oncology drugs
|
|
gptkbp:production_company
|
gptkb:Company
|
|
gptkbp:products
|
gptkb:Imbruvica
oral medication
new cancer drugs
|
|
gptkbp:receives_funding_from
|
venture capital funding
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
breakthrough therapy designation
|
|
gptkbp:research
|
targeted cancer therapies
|
|
gptkbp:research_areas
|
hematology
cancer therapeutics
treatment of blood cancers
|
|
gptkbp:research_focus
|
targeted therapies
hematologic malignancies
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:strategic_importance
|
improving cancer treatment
|
|
gptkbp:type_of
|
gptkb:Bruton_tyrosine_kinase_inhibitor
|
|
gptkbp:website
|
www.pharmacyclics.com
|